Financial Performance - For the quarter ended September 30, 2025, total revenues were $229.32 million, a decrease from $257.41 million in the previous quarter[25] - Room revenue for Q3 2025 was $139.52 million, compared to $154.06 million in Q2 2025, reflecting a decline of approximately 9.4%[25] - Net income for the quarter was $1.27 million, significantly lower than $19.31 million in the previous quarter, indicating a decrease of about 93.4%[25] - Total operating expenses for Q3 2025 were $217.48 million, down from $227.20 million in Q2 2025, representing a reduction of approximately 4.8%[25] - Corporate overhead expenses were $6.97 million for Q3 2025, a decrease from $8.35 million in Q2 2025, reflecting cost management strategies[25] - Net income for Q3 2025 was $1,322,000, with a trailing 12-month total of $18,187,000[27] - Adjusted EBITDAre for Q3 2025 was $50,052,000, with a trailing 12-month total of $228,083,000[27] - FFO attributable to common stockholders for Q3 2025 was $30,641,000, with a trailing 12-month total of $142,410,000[28] - Total Portfolio Revenues for Q3 2025 reached $229.32 million, a slight increase from $224.08 million in Q3 2024, reflecting a 1.0% growth[56] - Adjusted EBITDA for the Total Portfolio in Q3 2025 was $52.65 million, down from $56.13 million in Q3 2024, resulting in a margin decrease from 25.0% to 23.0%[56] - For the nine months ended September 30, 2025, the Total Portfolio Revenues were $715.71 million, compared to $698.76 million in the same period of 2024, marking a 2.4% increase[57] - The Adjusted EBITDA margin for the Total Portfolio for the nine months ended September 30, 2025, was 26.0%, a decrease from 26.9% in 2024[57] Debt and Capitalization - The company reported a loss on extinguishment of debt amounting to $180, indicating ongoing financial restructuring efforts[25] - Total debt as of September 30, 2025, was $930,000,000, representing 31.1% of total capitalization[34] - Market value of common equity increased to $1,779,474,000 as of September 30, 2025, compared to $1,650,681,000 in the previous quarter[34] - Total capitalization as of September 30, 2025, was $2,990,724,000[34] - The average interest rate on total debt was 5.16% as of September 30, 2025[37] Operational Metrics - The company owns 14 hotels with a total of 6,999 rooms, primarily under nationally recognized brands, focusing on long-term stakeholder value[8] - The total portfolio consists of 6,999 rooms across various hotels, with the Hilton San Diego Bayfront accounting for 1,190 rooms, representing 17% of the total[44] - For Q3 2025, the Hilton San Diego Bayfront reported an ADR of $281, occupancy of 85.5%, and RevPAR of $240, reflecting an 8.6% increase compared to Q3 2024[49] - The Hyatt Regency San Francisco achieved an ADR of $292, with occupancy at 86.8%, resulting in a RevPAR of $253, marking a 15.3% increase year-over-year[49] - The total portfolio's TRevPAR for Q3 2025 was $355, a 2.4% increase from Q3 2024[49] - The Andaz Miami Beach, which opened in May 2025, reported a 100% occupancy rate for Q3 2025, with an ADR of $305[49] - The Four Seasons Resort Napa Valley experienced a 9.3% decrease in ADR to $1,231, with occupancy at 59.5% for the nine months ended September 30, 2025[51] - The Montage Healdsburg's RevPAR for Q3 2025 was $701, down 6.6% from Q3 2024, with occupancy at 62.9%[49] Strategic Initiatives - Future strategies include potential acquisitions and dispositions of well-located hotel properties to enhance portfolio value[8] - The company emphasizes the importance of non-GAAP measures like FFO and Adjusted FFO to assess ongoing operational performance[15][16] - The company continues to focus on strategic renovations and acquisitions to enhance portfolio performance and operational efficiency[59] - The company acquired the remaining 25% interest in the Hilton San Diego Bayfront in June 2022, resulting in full ownership of the hotel[44] - The Series G cumulative redeemable preferred stock's dividend rate will increase to a minimum of 3.0% and 4.5% starting in Q1 and Q3 2024, respectively, and to at least 6.5% from Q3 2025, based on the Montage Healdsburg's annual net operating income yield[39] Renovation Impact - The Andaz Miami Beach, under renovation, reported a significant negative Adjusted EBITDA of $(2.49) million for Q3 2025, compared to $(0.56) million in Q3 2024[56] - The Hyatt Regency San Antonio Riverwalk, acquired in April 2024, showed a significant decline in Q3 2025 Adjusted EBITDA margin to 15.9%, down from 33.5% in Q3 2024[56] - The Marriott Long Beach Downtown, also undergoing renovation, showed a notable improvement in Q3 2025 with an Adjusted EBITDA margin of 23.3%, up from 11.6% in Q3 2024[56]

Revenue Growth - Total revenue increased by $19.1 million, or 11%, from $169.6 million in Q3 2024 to $188.6 million in Q3 2025[118] - Total revenue increased by $76.5 million, or 16%, from $466.2 million in the nine months ended September 30, 2024, to $542.7 million in the nine months ended September 30, 2025[118] - Advertiser revenue increased by $15.3 million, or 10%, in Q3 2025 compared to Q3 2024, driven by a 12% increase in Media Transactions Measured[119] - For the nine months ended September 30, 2025, total Advertiser revenue increased by $64.8 million, or 15%, compared to the same period in 2024, supported by a 17% increase in Media Transactions Measured[119] - Activation revenue increased by $9.9 million, or 10%, in Q3 2025 compared to Q3 2024, driven by greater adoption of Authentic Brand Suitability and core programmatic solutions[120] - For the nine months ended September 30, 2025, Activation revenue increased by $47.2 million, or 18%, compared to the same period in 2024[120] - Measurement revenue increased by $5.4 million, or 9%, to $65.4 million for the three months ended September 30, 2025, compared to the same period in 2024[121] - Supply-side revenue rose by $3.8 million, or 27%, to $17.8 million for the three months ended September 30, 2025, compared to the same period in 2024[122] Financial Performance - Operating income decreased by $4.6 million, or 18%, in Q3 2025 compared to Q3 2024[115] - Net income decreased by $7.999 million, or 44%, in Q3 2025 compared to Q3 2024[115] - The gross revenue retention rate was over 95% for the three months ended September 30, 2025[103] - Adjusted EBITDA for the three months ended September 30, 2025, was $65.9 million, with an Adjusted EBITDA margin of 35%[132] Expenses - Cost of revenue increased by $4.0 million, or 14%, to $33.5 million for the three months ended September 30, 2025, driven by higher partner costs and data services[123] - Product development expenses grew by $5.5 million, or 14%, to $44.8 million for the three months ended September 30, 2025, primarily due to increased personnel costs[124] - Sales, marketing, and customer support expenses increased by $6.5 million, or 16%, to $47.0 million for the three months ended September 30, 2025, mainly due to higher personnel costs[125] - General and administrative expenses rose by $4.0 million, or 17%, to $27.0 million for the three months ended September 30, 2025, largely due to increased personnel costs and legal fees[126] Cash Flow and Capital Management - As of September 30, 2025, the company had cash and cash equivalents of $200.7 million and net working capital of $156.3 million[135] - The company authorized a repurchase of up to $200.0 million of its outstanding common stock under the New Repurchase Program[143] - During the three months ended September 30, 2025, the company repurchased 3.3 million shares for an aggregate amount of $50.1 million under the New Repurchase Program[145] - The Company repurchased 8.4 million shares for a total of $132.3 million during the nine months ended September 30, 2025, with $90.0 million remaining authorized for repurchase[146] - Cash flows from operating activities for the nine months ended September 30, 2025, were $138.5 million, an increase from $122.3 million in 2024, driven by a net income of $21.3 million[150][151] - Cash used in investing activities was $93.8 million for the nine months ended September 30, 2025, including $82.6 million for the acquisition of Rockerbox[152] - Cash used in financing activities totaled $140.8 million for the nine months ended September 30, 2025, primarily due to share repurchases[153] - The Company reported a cash decrease of $92.0 million in cash, cash equivalents, and restricted cash for the nine months ended September 30, 2025[147] Other Financial Information - Non-cash charges included $42.3 million in depreciation and amortization and $78.7 million in stock-based compensation for the nine months ended September 30, 2025[150] - The Company experienced a $11.6 million decrease in trade receivables and a $5.0 million decrease in trade payables during the nine months ended September 30, 2025[150] - Cash flows from operating activities in 2024 were impacted by a $12.6 million increase in prepaid expenses and a $10.3 million decrease in trade receivables[151] - The Company has not experienced material changes in market risks as of September 30, 2025, compared to the previous year[157] - There are no current legal proceedings expected to materially affect the Company's financial condition[161]

NEWS RELEASE As previously announced, TDS will hold a teleconference on November 7, 2025, at 9:00 a.m. CST. Listen to the call live via the Events & Presentations page of investors.tdsinc.com. *Comparisons are 3Q'24 to 3Q'25 unless otherwise noted. Note that in September 2024, TDS sold its Hosted and Managed Services (HMS) operations. This 2024 transaction affects year-over-year revenue comparisons at the consolidated level. HMS operating revenues were $34 million in Q3 2024. TDS reports third quarter 2025 ...

Revenue Generation - The company has not generated any revenue from product sales to date and does not expect to do so in the foreseeable future, with revenues primarily from research collaboration and license agreements [100]. - The company has not generated any revenue from product sales and does not expect to do so until successful completion of clinical development and regulatory approval [127]. Research and Development Expenses - Research and development expenses for the three months ended September 30, 2025, increased by $3.7 million to $43.99 million compared to $40.34 million in the same period of 2024 [108]. - Research and development expenses for the nine months ended September 30, 2025, totaled $125.93 million, an increase of $4.74 million from $121.19 million in 2024 [113]. - Personnel expenses for research and development decreased by $5.99 million for the nine months ended September 30, 2025, primarily due to workforce reductions [113]. - The company anticipates an increase in research and development expenses as it advances product candidates and conducts clinical trials [103]. Clinical Trials and Product Development - The company plans to file IND and/or CTA for Wilson's Disease in the first half of 2026 and for AATD in mid-2026, leveraging its modular technology [97]. - The Phase 1/2 trial for PM359 in chronic granulomatous disease showed promising results, with the first patient achieving 71% dihydrorhodamine positivity by Day 60 [99]. - The company is focused on advancing its in vivo liver franchise, targeting Wilson's Disease and Alpha-1 Antitrypsin Deficiency [97]. Financial Position and Cash Flow - As of September 30, 2025, the company had cash, cash equivalents, and investments totaling $227.0 million, including restricted cash [120]. - The company entered into an Open Market Sale Agreement with Jefferies LLC to issue and sell shares of common stock for up to $300.0 million [121]. - In August 2025, the company issued 43,700,000 shares of common stock at a public price of $3.30 per share, resulting in net proceeds of approximately $138.4 million [122]. - For the nine months ended September 30, 2025, the net cash used in operating activities was $125.3 million, compared to $139.1 million for the same period in 2024 [123]. - The company reported a net loss of $155.1 million for the nine months ended September 30, 2025 [124]. - Net cash provided by financing activities for the nine months ended September 30, 2025, was $151.0 million, driven primarily by stock issuances [126]. - The company expects to require additional funding to support ongoing research and development activities and potential commercialization expenses [128]. - The company believes its existing cash and investments will be sufficient to fund operations into 2027, but acknowledges the possibility of exhausting resources sooner [128]. Other Income and Expenses - General and administrative expenses decreased by $2.9 million to $11.21 million for the three months ended September 30, 2025, compared to $14.10 million in 2024, primarily due to a reduction in personnel expenses [110]. - The company reported a total other income of $3.39 million for the three months ended September 30, 2025, compared to $1.71 million in 2024, driven by changes in fair value of short-term investments [111]. Risk Factors - The company is exposed to interest rate risk related to its investment portfolio, which totaled $227.0 million as of September 30, 2025 [141].

Raised Full-Year 2025 Adjusted EBITDA margin guidance to approximately 33% NEW YORK – November 7, 2025 – DoubleVerify ("DV") (NYSE: DV), the leading software platform for digital media measurement, data, and analytics, today announced financial results for the third quarter ended September 30, 2025. "We delivered 11% year-over-year growth in the third quarter, reflecting disciplined execution and continued progress across our key growth initiatives, while delivering stronger quarterly margins as we leverage ...

Financial Performance - Total revenues reached $370.8 million, reflecting an 11.2% year-over-year growth[4] - Membership revenues increased to $122.7 million, a 14.3% year-over-year rise[4] - Adjusted EBITDA was $53.8 million, up from $48.3 million in Q3 2024, with an Adjusted EBITDA margin of 15%[4][8] - Net loss attributable to Soho House & Co Inc. was $18.7 million, or $0.10 loss per share, including $14.0 million in non-cash foreign exchange losses[4] - For the 13 weeks ended September 28, 2025, the company reported a net loss of $17,010,000 compared to a net income of $718,000 for the same period in 2024, representing a significant decline[22] - Total revenues increased to $370,750,000 for the 13 weeks ended September 28, 2025, up from $333,368,000 in the prior year, marking a growth of 11%[27] - Adjusted EBITDA for the 13 weeks ended September 28, 2025, was $53,774,000, an increase of 11% from $48,281,000 in the same period of 2024[22] - Operating income for the 13 weeks ended September 28, 2025, was a loss of $6,004,000, compared to a profit of $37,884,000 in the prior year, indicating a substantial decrease[23] Membership and Growth - Total members grew by 0.8% year-over-year to 269,606, with Soho House members increasing by 2.8% to 213,830[11] - Membership revenues rose to $122,702,000 for the 13 weeks ended September 28, 2025, compared to $107,394,000 in 2024, reflecting a growth of 14%[27] - House Membership Revenues are primarily derived from annual membership fees and one-time legacy registration fees, with the latter no longer applicable to new members since April 4, 2022[33] - Membership revenues are influenced by the number of members, membership mix, and pricing, with higher prices generally in North America compared to the UK and Europe[43] Revenue Streams - In-House revenues were $126.1 million, a 4.5% increase year-over-year, with RevPAR up 2% on a like-for-like basis[4][8] - In-House revenues increased to $126,088,000 for the 13 weeks ended September 28, 2025, up from $120,658,000 in the previous year, showing a growth of 4%[27] - Other revenues rose to $122.0 million, marking a 15.8% year-over-year growth driven by Scorpios and Soho Home[4] - In-House revenues include all revenues generated within the Houses, such as food and beverage, accommodation, and spa services[34] Cash and Assets - Cash, cash equivalents, and restricted cash at the end of Q3 2025 totaled $148 million[10] - Cash flows from operating activities for the 39 weeks ended September 28, 2025, were $98,757,000, compared to $62,794,000 in the prior year, indicating improved cash generation[29] - The company ended the period with cash, cash equivalents, and restricted cash totaling $148,254,000, down from $156,318,000 at the beginning of the period[29] - Cash and cash equivalents as of September 28, 2025, totaled $142,490,000, a slight decrease from $142,816,000 as of September 29, 2024[30] - The company reported an increase in accounts receivable, net, to $68,317,000 as of September 28, 2025, down from $78,890,000 as of December 29, 2024[31] - Cash paid for income taxes increased to $7,268,000 for the 39 weeks ended September 28, 2025, compared to $3,768,000 for the same period in 2024[30] - Total assets increased to $2,684,224,000 as of September 28, 2025, compared to $2,443,512,000 as of December 29, 2024, reflecting a growth of approximately 9.8%[31] - Total liabilities rose to $3,033,128,000 as of September 28, 2025, up from $2,772,970,000 as of December 29, 2024, indicating an increase of about 9.4%[32] - The total current liabilities increased to $564,630,000 as of September 28, 2025, from $474,162,000 as of December 29, 2024, reflecting a rise of approximately 19.1%[32] Expansion and Operations - The company opened Soho Farmhouse Ibiza and enhanced Soho Farmhouse in the UK with new fitness amenities[3] - The company plans to further expand Soho Health Clubs in response to strong demand for health and wellness offerings[3] - As of September 28, 2025, Soho House & Co operates 46 Soho Houses and 8 Soho Works globally[50] - The company has expanded its portfolio to include Scorpios Beach Clubs in Mykonos and Bodrum, as well as The Ned locations in London, New York, and Doha[50] - Soho House & Co is the only company that has scaled a private membership network with a global presence since its inception in 1995[50] - The company offers a diverse membership platform that connects members through physical and digital spaces[50] - Soho Home, the company's interiors and lifestyle retail brand, is part of its broader offerings[50]

Array reports third quarter 2025 results CHICAGO (November 7, 2025) — Array Digital Infrastructure, Inc. (NYSE:AD) reported total operating revenues from continuing operations of $47.1 million for the third quarter of 2025, versus $25.7 million for the same period one year ago. Net income (loss) attributable to Array shareholders and related diluted earnings (loss) per share from continuing operations were $108.8 million and $1.25, respectively, for the third quarter of 2025 compared to $(95.9) million and ...

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments GERMANTOWN, Maryland, November 7, 2025 (GLOBE NEWSWIRE) – Barinthus Biotherapeutics plc (NASDAQ: BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance with curative potential, today announced its financial results for the quarter ended September 30, 2025, and provided an overview of the Company's corporate developme ...

Financial Performance - The net loss for Q3 2025 was $14.6 million, or $(0.36) per share, compared to a net loss of $21.1 million, or $(0.52) per share in Q2 2025[8]. - For the three months ended September 30, 2025, total revenue was $0, compared to $15.0 million for the same period in 2024, indicating a decline of 100%[16]. - The net loss for the three months ended September 30, 2025, was $14.6 million, compared to a net loss of $8.1 million for the same period in 2024, representing an increase in loss of approximately 80.5%[16]. - The company reported a comprehensive loss of $17.5 million for the three months ended September 30, 2025, compared to a comprehensive gain of $1.1 million in the same period of 2024[16]. - The accumulated deficit increased to $293.0 million as of September 30, 2025, from $237.7 million at the end of 2024, reflecting a rise of about 23.3%[15]. Cash and Assets - As of September 30, 2025, Barinthus Bio reported cash, cash equivalents, and restricted cash of $75.7 million, down from $87.8 million as of June 30, 2025, reflecting a decrease of $12.1 million due to operating activities and currency translation losses[4]. - As of September 30, 2025, total assets decreased to $109.2 million from $160.3 million as of December 31, 2024, representing a decline of approximately 31.9%[15]. - Total current assets fell to $86.8 million, down from $125.7 million, a decrease of about 30.9%[15]. - Total liabilities decreased to $24.6 million from $30.2 million, a reduction of approximately 18.1%[15]. Research and Development - Research and development expenses for Q3 2025 were $5.4 million, a decrease of $2.6 million from $8.0 million in Q2 2025, attributed to reduced activity in infectious disease and oncology programs[7]. - Research and development expenses for the nine months ended September 30, 2025, totaled $21.6 million, down from $33.9 million in the prior year, a decrease of approximately 36.2%[16]. - The company is actively seeking partners to advance its VTP-300 program in chronic hepatitis B and VTP-850 program in prostate cancer[6]. Operating Expenses - Operating expenses for the three months ended September 30, 2025, were $15.2 million, down from $24.6 million in the prior year, a decrease of approximately 38.2%[16]. - General and administrative expenses decreased to $5.2 million in Q3 2025 from $15.4 million in Q2 2025, primarily due to reduced unrealized losses on foreign exchange[8]. - Impairment of long-lived assets expense was $4.7 million in Q3 2025, reflecting a valuation less than the carrying value of net assets due to the merger agreement[8]. Future Outlook - Barinthus Bio expects to fund its operating expenses and capital expenditures into 2027 based on its current resources[4]. - The company anticipates single ascending dose data readout for VTP-1000 before the end of 2025, with multiple ascending dose data expected in the second half of 2026[5]. - A definitive merger agreement was announced to combine with Clywedog Therapeutics, expected to close in the first half of 2026, creating a combined company with an estimated cash runway extending through 2027[6]. - The proposed combination with Clywedog aims to diversify the pipeline and broaden the base of institutional investors, targeting metabolic and autoimmune diseases[2].

Financial Performance - Core business net sales increased by 6.4% to $138.4 million for Q3 2025 compared to $134.0 million in Q3 2024[6] - Net Loss narrowed to $(0.8) million, or $(0.01) per diluted share, compared to $(6.3) million, or $(0.05) per diluted share, in the prior year[6] - Adjusted EBITDA rose to $27.1 million, up from $22.1 million in Q3 2024[6] - Net sales for the thirteen weeks ended September 28, 2025, were $138,373,000, an increase of 3.2% compared to $134,038,000 for the same period in 2024[18] - Gross profit for the thirteen weeks ended September 28, 2025, was $59,839,000, reflecting a 14.4% increase from $52,306,000 in the prior year[18] - Operating income surged to $15,867,000 for the thirteen weeks ended September 28, 2025, a significant increase of 185.2% compared to $5,563,000 in the same period of 2024[18] - Net income for the thirteen weeks ended September 28, 2025, was a loss of $806,000, an improvement of 87.2% from a loss of $6,288,000 in the prior year[18] - Adjusted EBITDA for the thirteen weeks ended September 28, 2025, was $27,106 million, representing a 22.5% increase from $22,114 million in the prior year[27] - The net income margin improved to (0.6%) for the thirteen weeks ended September 28, 2025, compared to (4.7%) in the prior year[27] Cash Flow and Debt Management - Free Cash Flow improved to $5.5 million in Q3 2025, a $7 million increase from the previous year[6] - The company reported a net cash provided by operating activities of $7,430,000 for the thirteen weeks ended September 28, 2025, compared to a net cash used of $1,748,000 in the same period of 2024[22] - Total debt repayment reached $100 million since September 2023, lowering the leverage ratio to 3.9x, the lowest since 2022[5] - Total debt as of September 28, 2025, was $542,938 million, a decrease from $561,840 million at December 31, 2024[29] - The Bank-adjusted EBITDA leverage ratio was 3.91x as of September 28, 2025, compared to 4.17x at December 31, 2024[29] Guidance and Future Outlook - Full-year 2025 net sales guidance is set between $590 million and $605 million, reflecting a year-over-year growth of 2.5% to 5.1%[8] - Adjusted EBITDA guidance for the full year 2025 is projected between $120 million and $127 million[8] - The company plans to continue executing its strategic framework to drive long-term growth and operational efficiency[7] Asset and Liability Overview - Total assets increased to $1,165,114,000 as of September 28, 2025, compared to $1,133,320,000 as of December 31, 2024[20] - Cash and cash equivalents decreased to $50,723,000 as of September 28, 2025, down from $56,087,000 at the end of 2024[20] - Total liabilities rose to $725,377,000 as of September 28, 2025, compared to $712,168,000 as of December 31, 2024[20] Capital Expenditures - Capital expenditures for the thirty-nine weeks ended September 28, 2025, were $26,408,000, significantly higher than $2,727,000 in the prior year[22] Product and Market Performance - The company achieved approximately 7.3% growth in B2B channels and 4.2% growth in DTC orders in Q3 2025 compared to the same period last year[12] - Product innovation and strategic pricing initiatives contributed $11.3 million in revenue for Q3 2025 and $30.1 million year-to-date[12] - Free cash flow for the thirty-nine weeks ended September 28, 2025, was $30,319 million, down from $40,046 million in the same period of 2024[33] - Adjusted net income for the thirty-nine weeks ended September 28, 2025, was $16,535 million, compared to $12,282 million in the same period of 2024[31] - The adjusted diluted EPS for the thirty-nine weeks ended September 28, 2025, was $0.14, up from $0.10 in the same period of 2024[31]